FDA-cleared profile

JLK-SDH

JLK, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: JLK-SDH analyzes non-contrast head CT for suspected hemispheric subdural hemorrhage and sends notification to a clinician for review in parallel to standard care; PACS/mobile previews may be compressed and are non-diagnostic, while full patient evaluation and uncompressed diagnostic viewing remain required.

Clinical role
Triage and notification support
Images and patients
CT/CTA · Head
Key limitation
Keep in mind: Notification is not diagnostic and cannot replace full patient evaluation, uncompressed diagnostic image review, standard care, or physician judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: JLK-SDH analyzes non-contrast head CT for suspected hemispheric subdural hemorrhage and sends notification to a clinician for review in parallel to standard care; PACS/mobile previews may be compressed and are non-diagnostic, while full patient evaluation and uncompressed diagnostic viewing remain required.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head Input: Non-contrast head CT in DICOM format; the reviewed labeling does not state a narrower scanner, slice-thickness, or reconstruction requirement.
  • Who uses it?Intended users: Trained radiologists and clinicians responsible for reviewing suspected subdural hemorrhage
  • What does the software produce?Output: A notification that suspected subdural hemorrhage has been identified and should be reviewed; previews may be compressed through PACS and mobile applications, while diagnostic review uses non-compressed images.
  • What is its most important limitation?Key limitation: Notification is not diagnostic and cannot replace full patient evaluation, uncompressed diagnostic image review, standard care, or physician judgment.

Clinical takeaway. Clinical role: JLK-SDH analyzes non-contrast head CT for suspected hemispheric subdural hemorrhage and sends notification to a clinician for review in parallel to standard care; PACS/mobile previews may be compressed and are non-diagnostic, while full patient evaluation and uncompressed diagnostic viewing remain required.

Evidence takeaway. Evidence from the reviewed source record: Independent test used 560 non-contrast head CT scans, including 174 subdural hemorrhage-positive and 386 negative cases; training used 29,524 scans from U.S., Brazilian, and Korean institutions.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
JLK-SDH analyzes non-contrast head CT for suspected hemispheric subdural hemorrhage and sends notification to a clinician for review in parallel to standard care; PACS/mobile previews may be compressed and are non-diagnostic, while full patient evaluation and uncompressed diagnostic viewing remain required.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Triage and notification support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Non-contrast head CT in DICOM format; the reviewed labeling does not state a narrower scanner, slice-thickness, or reconstruction requirement.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
A notification that suspected subdural hemorrhage has been identified and should be reviewed; previews may be compressed through PACS and mobile applications, while diagnostic review uses non-compressed images.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult head-CT and acute neuroimaging workflow
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Trained radiologists and clinicians responsible for reviewing suspected subdural hemorrhage
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Notification is not diagnostic and cannot replace full patient evaluation, uncompressed diagnostic image review, standard care, or physician judgment.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Independent test used 560 non-contrast head CT scans, including 174 subdural hemorrhage-positive and 386 negative cases; training used 29,524 scans from U.S., Brazilian, and Korean institutions.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Independent test used 560 non-contrast head CT scans, including 174 subdural hemorrhage-positive and 386 negative cases; training used 29,524 scans from U.S., Brazilian, and Korean institutions.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
97.1% (95% CI 94.4%-99.4%) in the 560-case independent test.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported specificity
97.4% (95% CI 95.8%-99.0%) in the 560-case independent test.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

Sensitivity

97.1 percent

  • EndpointSubdural hemorrhage detection
  • Population560 independent non-contrast head CT scans; 174 positive and 386 negative
  • Tested versionJLK-SDH submitted in K243611; build not stated

Specificity

97.4 percent

  • EndpointSubdural hemorrhage detection
  • Population560 independent non-contrast head CT scans; 174 positive and 386 negative
  • Tested versionJLK-SDH submitted in K243611; build not stated

AUC

0.974 AUC

  • EndpointSubdural hemorrhage detection
  • Population560 independent non-contrast head CT scans
  • Tested versionJLK-SDH submitted in K243611; build not stated

JLK-SDH independent test and training evaluation

  • DesignRetrospective test set evaluation with separate multicountry training dataset
  • Population560 test-set head CT scans; training set contained 29,524 scans from U.S., Brazil, and Korea
  • Scopeexact submission
  • Tested versionJLK-SDH submitted in K243611; build not stated
  • Samplen=560
  • IndependenceIndependence not established

K243611

The FDA describes the test set as independent of training data and includes 174 SDH-positive and 386 negative cases; independence of investigators or sponsorship was not established.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast head CT in DICOM format; the reviewed labeling does not state a narrower scanner, slice-thickness, or reconstruction requirement.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH

  2. Routing

    Source context, not route validation: The FDA submission describes DICOM-compliant processing, PACS preview, mobile notification, and a JLK-hosted algorithm service; local interfaces and routing require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH

  3. AI processing

    Source context, not route validation: The exact FDA package describes the JLK-SDH algorithm hosted on JLK servers that receive head CT images forwarded from CT scanners, plus a mobile software module for receiving and toggling notifications. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "This algorithm, hosted on JLK servers, is designed to analyze non-contrast CT images of the head acquired on CT scanners and forwarded to JLK servers." … "The mobile software module that enables user to receive and toggle notifications for suspected subdural hemorrhages". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) K243611: JLK-SDH

  4. Returned objects

    Source context, not route validation: A notification that suspected subdural hemorrhage has been identified and should be reviewed; previews may be compressed through PACS and mobile applications, while diagnostic review uses non-compressed images.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH

  5. Viewer/worklist/report

    Unresolved route: A notification that suspected subdural hemorrhage has been identified and should be reviewed; previews may be compressed through PACS and mobile applications, while diagnostic review uses non-compressed images.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the JLK-SDH algorithm hosted on JLK servers that receive head CT images forwarded from CT scanners, plus a mobile software module for receiving and toggling notifications. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "This algorithm, hosted on JLK servers, is designed to analyze non-contrast CT images of the head acquired on CT scanners and forwarded to JLK servers." … "The mobile software module that enables user to receive and toggle notifications for suspected subdural hemorrhages". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The FDA submission describes DICOM-compliant processing, PACS preview, mobile notification, and a JLK-hosted algorithm service; local interfaces and routing require confirmation.
  • Exact FDA submission
  • Checked 2026-09-06
Security
JLK's security page states a security program aligned with SOC 2 and HIPAA, AWS hosting in US regions with VPC isolation, TLS 1.2+ in transit, AES-256 at rest with KMS, role-based access, mandatory MFA for internal users, annual external penetration testing and security training. It states alignment, not an attestation report. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

PACS and mobile notification workflow

The exact submission describes a JLK-hosted DICOM service that can send notifications and provide compressed previews through PACS and mobile applications while directing clinicians to uncompressed diagnostic review.

exact submission · checked 2026-09-06

MEDIHUB Stroke family scope

JLK's official MEDIHUB Stroke page describes a family platform spanning CT, CTA, MRI, and MRA algorithms, including JLK-ICH and JLK-LVO; current JLK-SDH packaging and local integration require confirmation.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243611
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Head
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
26Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "JLK ICH SDH reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243611: JLK-SDH

    U.S. Food and Drug Administration - Published 2025-03-03 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Jlk-SDH model card (K243611)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. MEDIHUB Stroke official product page

    JLK - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

  8. JLK Security and Compliance

    JLK - Accessed 2026-10-25

    Scope: security

Research history

  1. K243611 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K213319

Viz ANEURYSM, Viz ANX

Viz.ai, Inc.

Authorized purpose: Triage and notification of suspected head aneurysms during routine care; not a diagnostic device.

Modality
CT/CTA
Anatomy
Head
Decision
2022-02-18
FDA-cleared K212261

StrokeSENS LVO

Circle Neurovascular Imaging, Inc

Authorized purpose: Triage and notify clinicians of suspected large-vessel occlusion on head CTA images.

Modality
CT/CTA
Anatomy
Head
Decision
2021-10-14
FDA-cleared K253560

Enhanced Boundary for PCCT

Ge Medical Systems, LLC

Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.

Modality
CT/CTA
Anatomy
Head
Decision
2026-06-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history